Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Pharmaceutical Technology

05:59 EDT 19th August 2018 | BioPortfolio

Here are the most relevant search results for "Pharmaceutical Technology" found in our extensive news archives from over 250 global news sources.

More Information about Pharmaceutical Technology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmaceutical Technology for you to read. Along with our medical data and news we also list Pharmaceutical Technology Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmaceutical Technology Companies for you to search.

Showing News Articles 1–25 of 927 from Pharmaceutical Technology

Friday 17th August 2018

How safe is your process? The usual causes of pharmaceutical contamination

Large-scale plant shutdowns are somewhat rare in the pharmaceutical industry, given the high level of care that manufacturers must take...Read More... The post How safe is your process? The usual causes of pharmaceutical contamination appeared first on Pharmaceutical Technology.

ILC Dover flexible isolators: A cost-effective way to maximise containment

High potency active pharmaceutical ingredients (HP APIs) are the fastest growing segment of the API market.  This is mainly due...Read More... The post ILC Dover flexible isolators: A cost-effective way to maximise containment appeared first on Pharmaceutical Technology.

So you want to break into the Chinese vaccine market?

Last week, one of China’s largest vaccine makers, Changchun Changsheng Biotechnology, was exposed for selling and distributing hundreds of thousands...Read More... The post So you want to break into the Chinese vaccine market? appeared first on Pharmaceutical Technology.

Revlimid demonstrates positive phase III results in Indolent NHL

Celgene has announced positive new data for its leading blockbuster drug, Revlimid (lenalidomide), which earned revenues of $8.2bn in 2017....Read More... The post Revlimid demonstrates positive phase III results in Indolent NHL appeared first on Pharmaceutical Technology.

After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics

On July 24, Nabriva Therapeutics announced the acquisition of Zavante Therapeutics, a biotechnology company developing treatments for the infections that...Read More... The post After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics appeared first on Pharmaceutical Technology.

Thursday 16th August 2018

Deals and M&As this week: Aralez Pharmaceuticals, Perrigo, Takeda

Aralez Pharmaceuticals has entered two purchase agreements to sell its main operating businesses, Vimovo and Toprol-XL, for $250m. The two...Read More... The post Deals and M&As this week: Aralez Pharmaceuticals, Perrigo, Takeda appeared first on Pharmaceutical Technology.

NUI Galway finds new treatment strategy for breast cancer relapse

Researchers from the National University of Ireland Galway (NUI Galway) have discovered a new treatment strategy to enhance the response...Read More... The post NUI Galway finds new treatment strategy for breast cancer relapse appeared first on Pharmaceutical Technology.

Fasinumab Phase III osteoarthritis trial meets endpoints

Teva Pharmaceutical and Regeneron Pharmaceuticals have reported positive top-line data from a phase III clinical trial of fasinumab to treat...Read More... The post Fasinumab Phase III osteoarthritis trial meets endpoints appeared first on Pharmaceutical Technology.

BioNTech signs $425m flu vaccine deal with Pfizer

German biopharmaceutical company BioNTech has signed a research and development (R&D) agreement with Pfizer for the development of mRNA-based vaccines...Read More... The post BioNTech signs $425m flu vaccine deal with Pfizer appeared first on Pharmaceutical Technology.

BioNTech signs a $425m flu vaccine deal with Pfizer

German biopharmaceutical company BioNTech has signed a research and development (R&D) agreement with Pfizer for the development of mRNA-based vaccines...Read More... The post BioNTech signs a $425m flu vaccine deal with Pfizer appeared first on Pharmaceutical Technology.

EMA gives PRIME status to promising Huntington’s treatment

PRIME is the European Medicines Agency (EMA) Priority Medicines scheme to support the development of medicines that meet a high...Read More... The post EMA gives PRIME status to promising Huntington’s treatment appeared first on Pharmaceutical Technology.

UK seeks harmony with EU CTR as NHS and pharma stockpile drugs

The Medicines Health Products Regulatory Agency has reaffirmed its commitment to follow the European Clinical Trials Regulation System (CTR) during...Read More... The post UK seeks harmony with EU CTR as NHS and pharma stockpile drugs appeared first on Pharmaceutical Technology.

Realm Therapeutics unveils phase II failure of PR022 for severe eczema

US-based Realm Therapeutics has announced its drug candidate PR022 for atopic dermatitis has failed to achieve its primary endpoint in...Read More... The post Realm Therapeutics unveils phase II failure of PR022 for severe eczema appeared first on Pharmaceutical Technology.

Janssen and ViiV report positive results for two drug regimen for HIV-1

Johnson & Johnson subsidiary Janseen Pharmaceuticals and ViiV Healthcare have reported positive topline results from their phase III trial of...Read More... The post Janssen and ViiV report positive results for two drug regimen for HIV-1 appeared first on Pharmaceutical Technology.

Hackers can fool doctors with fake vital signs, but only the rich and powerful need to worry

It sounds like something out of a thriller: a hacker sneaks into the hospital room of a high-profile target and...Read More... The post Hackers can fool doctors with fake vital signs, but only the rich and powerful need to worry appeared first on Pharmaceutical Technology.

Wednesday 15th August 2018

RXi and Karolinska Institutet target solid tumour therapy

US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with the Karolinska Institutet in Stockholm, Sweden, to develop and...Read More... The post RXi and Karolinska Institutet target solid tumour therapy appeared first on Pharmaceutical Technology.

US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment

The US Food & Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) by Motif Bio...Read More... The post US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment appeared first on Pharmaceutical Technology.

US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment

The US Food & Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) by Motif Bio...Read More... The post US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment appeared first on Pharmaceutical Technology.

NIH-funded study reverses congenital blindness in mice

A study funded by the National Institutes of Health’s (NIH) National Eye Institute (NEI) has successfully reversed congenital blindness by...Read More... The post NIH-funded study reverses congenital blindness in mice appeared first on Pharmaceutical Technology.

NICE does not recommend NHS use of Biogen’s nusinersen for SMA

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Biogen’s Spinraza (nusinersen) for routine use by...Read More... The post NICE does not recommend NHS use of Biogen’s nusinersen for SMA appeared first on Pharmaceutical Technology.

Study shows remifentanil better at relieving pain in labour than current standard care

An alternative opioid pain relief drug, remifentanil, can better relieve pain and reduces the need for an epidural for pregnant...Read More... The post Study shows remifentanil better at relieving pain in labour than current standard care appeared first on Pharmaceutical Technology.

Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth

Scientists have been digging deep in the dirt microbiome for decades in search of potential new drug compounds, successfully developing...Read More... The post Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth appeared first on Pharmaceutical Technology.

Tuesday 14th August 2018

Mustang Bio licenses gene therapy for bubble boy disease

US-based biopharmaceutical firm Mustang Bio has entered an exclusive worldwide licence agreement with St. Jude Children’s Research Hospital for a...Read More... The post Mustang Bio licenses gene therapy for bubble boy disease appeared first on Pharmaceutical Technology.

Mustang Bio licences gene therapy for bubble boy disease

US-based biopharmaceutical firm Mustang Bio has entered into an exclusive worldwide license agreement with St. Jude Children’s Research Hospital for...Read More... The post Mustang Bio licences gene therapy for bubble boy disease appeared first on Pharmaceutical Technology.

Shire submits NDA in Japan for Intuniv to treat ADHD

Irish biotechnology company Shire, through its partner Shionogi, has filed a new drug application (NDA) in Japan seeking approval to...Read More... The post Shire submits NDA in Japan for Intuniv to treat ADHD appeared first on Pharmaceutical Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks